NCT02326194View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

July 31, 2015

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

Low dose Ebola Zaire vaccine (Ad5-EBOV)

one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)

BIOLOGICAL

High dose Ebola Zaire vaccine (Ad5-EBOV)

two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.

BIOLOGICAL

placebo (one dose)

placebo, one doses

BIOLOGICAL

placebo (two doses)

placebo, two doses, with one dose to each arm at a same time.

Trial Locations (1)

Unknown

Phase 1 vaccine clinical trial center of Jiangsu Provincial Center for Disease Control and Prevention, Taizhou

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

collaborator

Tianjin Cansino Biotechnology Inc

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK